AESARA Europe
Preparation
- European Landscape Assessment
- HTA Decision Analysis
- Payer Research and Advisory Boards
- EU Joint Scientific Consultation
- Key Country Market Insights
- EU JCA PICO prediction
Strategy
- European HTA, price & reimbursement strategy
- Lifecycle Management (LCM) Strategy
- Value Story & Message Development
- Evidence Gap Analysis
- Evidence Generation Planning (incl. RWE & PLEG)
- Value-based Price Potential
- EU HTA/JCA Strategy
- EU JCA process & governance design
Questions we answer
Strategy leaders
Kate Burslem, MSc
has over 20 years’ experience in the healthcare field in Europe and the US. She joins AESARA from AbbVie, where she most recently led the global HEOR team supporting AbbVie’s Toxin Therapeutic & Eyecare portfolios, having previously held leadership positions in the Neuroscience & Gastrointestinal therapeutic areas. Before joining AbbVie, Kate held positions of increasing responsibility in HEOR at Boehringer Ingelheim, within both the US and UK affiliates. Prior to joining the pharmaceutical industry, Kate worked as a Technical Analyst at the UK’s National Institute for Health & Care Excellence. She began her career in employee benefits consulting, where her work on international medical insurance plan design inspired her to go back to school and study health economics.
Kate has a strategic mindset, coupled with strong analytical skills in the key HEOR disciplines of real-world evidence, economic modeling and patient-reported outcomes. She enjoys developing value and access strategies at all stages of the product lifecycle and fostering alignment across multi-disciplinary teams to achieve a common goal. Her career has spanned a broad range of therapeutic areas including immunology, oncology, neuroscience, respiratory, cardiovascular and diabetes.
Catherine Chamoux, PhD
has international experience acquired over thirty+ years in the pharma industry in medium-sized and large companies. She holds a PhD in Pharmacy and a Masters of Public Health from Sciences Po, Paris. She is an expert in Market Access for innovative drugs.
As a member of the leadership team of the French affiliate of a leading US biotech for 15 years, she helped establish & develop the company locally, directly negotiated product prices & access conditions, developed relationships with regulators, payors and KOLs. She also actively participated in the evidence generation and early access program strategies for our innovative therapies, including orphan drug products, highlighting the unmet needs and the products’ unique attributes.
She also has strong pan-European experience in Market Access, having most recently led the Market Access Excellence function for Europe, creating common understanding, tools, measures and co-operation between countries.
